JEFFS ROGER sold $2.5M of LQDA

JEFFS ROGER (Chief Executive Officer) sold 35,249 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $2.52M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · JEFFS ROGER
Published Jul 15, 2026, 12:07 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest actionable element is the specific trade size, price range, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as a routine 10b5-1 sale, with limited fundamental implications, but it can marginally influence short-term sentiment.

03

What to watch

The filing does not disclose reasons for the sale, and the weighted-average price range ($71.39 to $71.52) suggests execution around prevailing market levels rather than a distressed sale.

Relevance 5/10Novelty 4/10Timing: SEC Form 4 filed 2026-07-14 for sales executed 2026-07-13

Background

The article is an SEC Form 4 insider transaction disclosure for Liquidia Corp, reporting CEO Jeffs Roger’s open-market sale of shares.

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia CEO Jeffs Roger sold 35,249 shares in open-market trades at about $71.51, per a newly filed SEC Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief unless paired with other company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but the trades are explicitly under a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific insider activity without sector-wide information.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with periods of reduced confidence or liquidity needs, so traders may still watch for follow-on selling patterns.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure.

  • Jeffs Roger

    CEO and director reporting the sale of shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.